Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094810316> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2094810316 abstract "Pritumumab is a natural human IgG1 kappa antibody that has been derived from a B cell isolated from regional draining lymph node of a cervical carcinoma patient. Specificity analysis of the antibody with human tissues showed the target antigen, altered tumor-associated vimentin, to be highly restricted to various epithelial cancers and not normal cells and tissues. In various Phase II clinical trials in Japan 249 patients with brain cancer were treated with the antibody. Overall response rate was between 25-30%, a 9-fold increase over standard care, with several survivors beyond 5-years post-treatment. Patients were on al ow dose regimen of 1m g given twice aw eek for a course of 24 weeks, suggesting Pritumumab to be safe and effective in patients with brain cancer. However, the yield from human-hybridoma was only about 1 picogram per cell per day. Therefore, there is a pressing need to produce adequate amount of GMP grade Pritumumab in ac ost effective manner. The GPEx ® technology of Catalent was adapted to develop a Pritumumab-secreting Chinese hamster ovary (CHO) cell line. This involved construction and cloning of heavy and light chain DNAs into an expression vector and transduced into HEK 293 cells that constitutively produce the MLV gag, pro ,a ndpol. The Pritumumab cell line was made by performing multiple rounds of transduction (multiplicity of > 1000 retrovector particles/cell) of the GPEx ® parental cell line (GCHO) with retrovector made from the gene construct developed to express the Pritumumab antibody light and heavy chains. Five independent transductions were performed: two LC and three HC. Limiting dilution method was used to establish cloned cell lines. Top clones were selected based on antibody titer as determined by Protein A HPLC using a generic IgG standard. Single copies of genes were inserted efficiently in unique locations throughout the genome of the CHO cells to obtain genetically stable cell line that expressed high levels of the antibody. The selected clone represented more than a 40-fold increased production of the antibody over the original human-hybridoma. Flow cytometry binding and immunohistochemical analyses demonstrated comparability between the recombinant and the hybridoma forms of the protein. Furthermore, amino acid compositions of the two forms are identical. Thus, high level of specific productivity and titer of the CHO clone will allow the therapeutic antibody program to move forward into large and extended clinical trials of not only brain cancers but also of other types of cancers as well." @default.
- W2094810316 created "2016-06-24" @default.
- W2094810316 creator A5023433820 @default.
- W2094810316 creator A5090596847 @default.
- W2094810316 date "2014-11-06" @default.
- W2094810316 modified "2023-09-29" @default.
- W2094810316 title "Human hybridoma and recombinant Pritumumab antibodies for treatment of human solid tumors" @default.
- W2094810316 doi "https://doi.org/10.1186/2051-1426-2-s3-p149" @default.
- W2094810316 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4288481" @default.
- W2094810316 hasPublicationYear "2014" @default.
- W2094810316 type Work @default.
- W2094810316 sameAs 2094810316 @default.
- W2094810316 citedByCount "1" @default.
- W2094810316 countsByYear W20948103162019 @default.
- W2094810316 crossrefType "journal-article" @default.
- W2094810316 hasAuthorship W2094810316A5023433820 @default.
- W2094810316 hasAuthorship W2094810316A5090596847 @default.
- W2094810316 hasBestOaLocation W20948103161 @default.
- W2094810316 hasConcept C104317684 @default.
- W2094810316 hasConcept C111599444 @default.
- W2094810316 hasConcept C153911025 @default.
- W2094810316 hasConcept C159654299 @default.
- W2094810316 hasConcept C174510640 @default.
- W2094810316 hasConcept C175656101 @default.
- W2094810316 hasConcept C203014093 @default.
- W2094810316 hasConcept C2780849966 @default.
- W2094810316 hasConcept C36394416 @default.
- W2094810316 hasConcept C502942594 @default.
- W2094810316 hasConcept C54009773 @default.
- W2094810316 hasConcept C54355233 @default.
- W2094810316 hasConcept C55493867 @default.
- W2094810316 hasConcept C71924100 @default.
- W2094810316 hasConcept C81885089 @default.
- W2094810316 hasConcept C86803240 @default.
- W2094810316 hasConceptScore W2094810316C104317684 @default.
- W2094810316 hasConceptScore W2094810316C111599444 @default.
- W2094810316 hasConceptScore W2094810316C153911025 @default.
- W2094810316 hasConceptScore W2094810316C159654299 @default.
- W2094810316 hasConceptScore W2094810316C174510640 @default.
- W2094810316 hasConceptScore W2094810316C175656101 @default.
- W2094810316 hasConceptScore W2094810316C203014093 @default.
- W2094810316 hasConceptScore W2094810316C2780849966 @default.
- W2094810316 hasConceptScore W2094810316C36394416 @default.
- W2094810316 hasConceptScore W2094810316C502942594 @default.
- W2094810316 hasConceptScore W2094810316C54009773 @default.
- W2094810316 hasConceptScore W2094810316C54355233 @default.
- W2094810316 hasConceptScore W2094810316C55493867 @default.
- W2094810316 hasConceptScore W2094810316C71924100 @default.
- W2094810316 hasConceptScore W2094810316C81885089 @default.
- W2094810316 hasConceptScore W2094810316C86803240 @default.
- W2094810316 hasLocation W20948103161 @default.
- W2094810316 hasLocation W20948103162 @default.
- W2094810316 hasLocation W20948103163 @default.
- W2094810316 hasOpenAccess W2094810316 @default.
- W2094810316 hasPrimaryLocation W20948103161 @default.
- W2094810316 hasRelatedWork W1019011926 @default.
- W2094810316 hasRelatedWork W1504263203 @default.
- W2094810316 hasRelatedWork W1538974736 @default.
- W2094810316 hasRelatedWork W1540461751 @default.
- W2094810316 hasRelatedWork W1590397898 @default.
- W2094810316 hasRelatedWork W1979603123 @default.
- W2094810316 hasRelatedWork W1982040395 @default.
- W2094810316 hasRelatedWork W2008920151 @default.
- W2094810316 hasRelatedWork W2011465285 @default.
- W2094810316 hasRelatedWork W2014132484 @default.
- W2094810316 hasRelatedWork W2026788309 @default.
- W2094810316 hasRelatedWork W2045789031 @default.
- W2094810316 hasRelatedWork W2064426568 @default.
- W2094810316 hasRelatedWork W2076328260 @default.
- W2094810316 hasRelatedWork W2092810942 @default.
- W2094810316 hasRelatedWork W2167477934 @default.
- W2094810316 hasRelatedWork W2363928286 @default.
- W2094810316 hasRelatedWork W2371096960 @default.
- W2094810316 hasRelatedWork W72995599 @default.
- W2094810316 hasRelatedWork W2775644648 @default.
- W2094810316 isParatext "false" @default.
- W2094810316 isRetracted "false" @default.
- W2094810316 magId "2094810316" @default.
- W2094810316 workType "article" @default.